Financial reports
ARS
2023 FY
Annual report to shareholders
28 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
10-K
2022 FY
Annual report
22 Feb 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
23 Feb 22
Current reports
8-K
Gilead Sciences Announces Completion of Acquisition of Cymabay
22 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
8-K
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
8-K
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
2 Feb 24
8-K
Gilead Sciences Announces Third Quarter 2023 Financial Results
7 Nov 23
8-K
Entry into a Material Definitive Agreement
14 Sep 23
8-K
Regulation FD Disclosure
16 Aug 23
8-K
Gilead Sciences Announces Second Quarter 2023 Financial Results
3 Aug 23
8-K
Departure of Directors or Certain Officers
5 May 23
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
20 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
11 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
28 Feb 24
SC TO-T
Third party tender offer statement
23 Feb 24
SC TO-C
Information about tender offer
14 Feb 24
SC TO-C
Information about tender offer
12 Feb 24
SC TO-C
Information about tender offer
12 Feb 24
424B5
Prospectus supplement for primary offering
11 Sep 23
Proxies
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
PX14A6G
Letter to shareholders
6 Apr 23
DEFR14A
Revised proxy
5 Apr 23
PX14A6G
Letter to shareholders
29 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
PX14A6G
Letter to shareholders
11 Apr 22
PX14A6G
Letter to shareholders
6 Apr 22
Other
UPLOAD
Letter from SEC
5 May 23
CORRESP
Correspondence with SEC
25 Apr 23
UPLOAD
Letter from SEC
29 Mar 23
CT ORDER
Confidential treatment order
2 Feb 22
CORRESP
Correspondence with SEC
2 Oct 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
28 Jan 20
CT ORDER
Confidential treatment order
12 Jul 19
Ownership
SC 13G
Xilio Therapeutics, Inc.
5 Apr 24
4
Xilio Therapeutics, Inc.
3 Apr 24
3
Xilio Therapeutics, Inc.
3 Apr 24
4
Merdad Parsey
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Kevin E Lofton
29 Mar 24
4
Deborah H Telman
12 Mar 24
4
Sandra Patterson
12 Mar 24
4
Merdad Parsey
11 Mar 24
4
Daniel Patrick O'Day
11 Mar 24